Abstract Details
Activity Number:
|
324
|
Type:
|
Contributed
|
Date/Time:
|
Tuesday, August 11, 2015 : 8:30 AM to 10:20 AM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #315386
|
|
Title:
|
Some Thoughts on Benefit-Risk Assessment for Drug Development
|
Author(s):
|
Qi Jiang*
|
Companies:
|
Amgen
|
Keywords:
|
benefit:risk ;
QSPI ;
Future Direction
|
Abstract:
|
Much increased emphasis has been placed on the structured benefit:risk assessment for drug development globally. This whole session is about the benefit:risk efforts from QSPI Benefit:Risk Working Group. This presentation is to discuss and comment on a few key aspects of the Working Group efforts and to point out future direction in the benefit:risk area.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2015 program
|
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.